Expertise in
18
conditions

Dr. Connie Batlevi

Oncology
Memorial Sloan Kettering Cancer Center
1275 York Ave, 
New York, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
18
conditions
Memorial Sloan Kettering Cancer Center
1275 York Ave, 
New York, NY 

Overview

Connie Batlevi is an Oncologist in New York, New York. Dr. Batlevi is highly rated in 18 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 67 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in NY

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Memorial Sloan Kettering Cancer Center
1275 York Ave, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: March 02, 2026
Intervention Type: Combination product, Drug
Study Drugs: Tazemetostat, Lenalidomide, Rituximab
Study Phase: Phase 3
An Exploratory Study to Correlate the Level of Cell-free DNA With Response to First-line Treatment in Patients With Follicular Lymphoma
An Exploratory Study to Correlate the Level of Cell-free DNA With Response to First-line Treatment in Patients With Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: August 19, 2025
Intervention Type: Diagnostic test, Other
Study Phase: Phase 1
Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma
Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2025
Intervention Type: Drug
Study Drug: N-Acetylcysteine
Study Phase: Phase 1
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: July 14, 2025
Intervention Type: Biological
Study Drugs: AUTO3, cyclophosphamide, fludarabine, pembrolizumab
Study Phase: Phase 1/Phase 2
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drug: Abexinostat
Study Phase: Phase 2
Phase I/II Clinical Trial of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Phase I/II Clinical Trial of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: December 14, 2022
Intervention Type: Drug
Study Drugs: Copanlisib, Ibrutinib
Study Phase: Phase 1/Phase 2
Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma
Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma
Enrollment Status: Completed
Publish Date: October 10, 2022
Intervention Type: Drug
Study Drugs: Buparlisib, Ibrutinib
Study Phase: Phase 1
View 5 Less Clinical Trials

67 Total Publications

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 02, 2025
Similar Doctors
Expertise in
33
conditions
Dr. Alison Moskowitz
Hematology | Oncology
Expertise in
33
conditions
Dr. Alison Moskowitz
Hematology | Oncology

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.3 miles away)
332-456-0508
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alison Moskowitz is a Hematologist and an Oncologist in New York, New York. Dr. Moskowitz is highly rated in 33 conditions, according to our data. Her top areas of expertise are T-Cell Lymphoma, Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Moskowitz is currently accepting new patients.

Expertise in
26
conditions
Dr. Steven Horwitz
Hematology | Oncology
Expertise in
26
conditions
Dr. Steven Horwitz
Hematology | Oncology

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.3 miles away)
646-535-8986
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Horwitz is a Hematologist and an Oncologist in New York, New York. Dr. Horwitz is highly rated in 26 conditions, according to our data. His top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, and Bone Marrow Aspiration. Dr. Horwitz is currently accepting new patients.

Expertise in
27
conditions
Dr. Gilles Salles
Hematology | Oncology
Expertise in
27
conditions
Dr. Gilles Salles
Hematology | Oncology

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.3 miles away)
929-298-9410
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gilles Salles is a Hematologist and an Oncologist in New York, New York. Dr. Salles is highly rated in 27 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Bone Marrow Transplant, and Splenectomy. Dr. Salles is currently accepting new patients.

Frequently Asked Questions about Dr. Connie Batlevi

How do I make an appointment with Dr. Connie Batlevi?

You can book an appointment with Dr. Connie Batlevi by calling their office at 212-639-2000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Connie Batlevi a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Connie Batlevi is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Connie Batlevi specialize in?

While Dr. Connie Batlevi is a Oncology, they have specific expertise in Non-Hodgkin Lymphoma, Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Connie Batlevi participate in research or clinical trials?

Yes. Dr. Connie Batlevi has published 67 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Connie Batlevi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Connie Batlevi accept my insurance?

Dr. Connie Batlevi accepts most major insurance plans, including Anthem BCBS and MetroPlus Health. We recommend calling the office directly at 212-639-2000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Batlevi's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile